PharmaEssentia Korea said it hosted a myeloproliferative neoplasms (MPN) forum to share the latest insights on Besremi (ropeginterferon alfa-2b), a treatment for polycythemia vera (PV) on Thursday last week.The forum featured two world-renowned experts in the field of MPN -- Professor Hans Carl Hass
Janssen's Rybrevant (amivantamab), a treatment for EGFR exon20 insertion non-small cell lung cancer (NSCLC), a rare form of lung cancer with a poor prognosis, is making its third attempt to get reimbursement in Korea.The drug’s third challenge for insurance coverage comes when the “nominality” of th
NKMAX, a local biotech firm specializing in NK cell therapy, announced plans to file an objection to its potential delisting from the Korea Exchange (KRX).The company, which has been listed on the Kosdaq since August 2018, is facing delisting due to significant operational challenges.On March 5, NKM
GSK's Shingrix, the world's only shingles vaccine that can be given to immunocompromised individuals such as cancer patients, is notorious for causing pain, unlike any other vaccine, from the moment it is given to three to four days afterward.So why is it so painful to receive Shingrix, a recombinan
AbbVie Korea's psoriatic disease treatment Skyrizi (risankizumab) won approval from the Ministry of Food and Drug Safety (MFDS) on Tuesday for treating moderate-to-severe pustular psoriasis of the hands and feet in adults (18 years and older) who have had an inadequate response to or are intolerant
Recent advancements in HIV treatment and prevention, including the roll-out of pre-exposure prophylaxis (PrEP) and the bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) treatment regimen, have highlighted the critical need for ethnic-centered approaches in healthcare.Therefore, understanding
GI Innovation is accelerating the development of a subcutaneous (SC) formulation of its immuno-oncology candidate GI-102.The company said Tuesday that it has applied for approval to change the IND (investigational new drug) application for the GI-102 phase 1/2a clinical trial to the Ministry of Food
Saruparib, a next-generation PARP inhibitor in development by AstraZeneca, has garnered attention from cancer experts worldwide after showing clinical benefit in patients with homologous recombination repair-deficient (HRD) breast cancer.However, it is questionable whether Korean patients who face s
Curocell, a local chimeric antigen receptor-T (CAR-T) developer, said it will start developing a next-generation Anti-CD19 CAR-T therapy for treatment-resistant systemic lupus erythematosus (SLE) as part of the2024 Multi-Ministerial Regenerative Medicine Technology Development Program.This initiativ
Hugel, a total medical aesthetics company, said Tuesday that its polydioxanone (PDO) suture brand Licellvi (domestic product name: Blue Rose Forte) has received a product license from the Brazilian National Agency for Food and Drug Surveillance (ANVISA).Licellvi is a PDO suture brand of JWorld, a su
An increasing number of health supplements are differentiating themselves from traditional forms, such as capsules and pills, to various formulations, attempting to attract consumers with formulations that focus on portability and convenience of consumption.CJ ENM's digital marketing affiliate, Mezz
Daewoong Pharmaceutical said that it applied for product approval for Envlo, the first homegrown sodium-glucose cotransporter 2 (SGLT2) diabetes drug in Korea and the nation's 36th newly developed drug, to Mexico's Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS).COFEPRIS is
Celltrion said it has completed a registration contract for its subcutaneous (SC) Remicade biosimilar, Zymfentra (infliximab), with one of the top three pharmaceutical benefit managers (PBMs) in the United States."We are pleased to announce through our website that we have successfully closed a deal
EuBiologics, a Korean vaccine maker targeting the global public health market, said it opened a new office at the Cambridge Innovation Center (CIC) in Boston, one of the largest biotech clusters in the world.EuBiologics' new office opening comes after their selection by KHIDI (Korea Health Industry
In a move signaling a potential resolution to ongoing family disputes, Hanmi Science, the holding company of Hanmi Pharm, announced the appointment of Lim Jong-hoon as co-CEO alongside the current chairperson, Song Young-sook.The decision came during a board meeting held at Hanmi headquarters in Son
BR Pharm, a regenerative medicine company, said it would present "Minimizing Procedural Pain and Maintaining Effectiveness" related to HP VITARAN, a skin booster using PN (Polynucleotide Sodium), at APS (AESTHETIC PLASTIC SURGERY) 2024, which will be held at the Grand InterContinental Seoul Parnas S
Eylea Injection 8 mg (aflibercept), which sharply increased the dose from the existing Eylea Injection 2 mg,, has won approval in Korea, drawing attention to whether it will be able to defend its leading position in the retinal disease market from Roche's Vabysmo (faricimab) and Eylea biosimilars.On
The Fair Trade Commission (FTC) is reportedly looking into Novo Nordisk Korea over allegations of monopolistic practices related to the cessation of its needle supply, NovoFine Plus pen needle.On Thursday, Joongang Ilbo, a Korean daily newspaper, first reported that the FTC's Seoul office dispatched
GC Cell, a contract development and manufacturing organization (CDMO) for cell and gene therapies, said Thursday that it has ushered in Kang Jin-hee, a clinical development and global regulatory expert, as its chief development officer to strengthen its R&D capabilities.According to GC Cell, the new
Boryung (formerly Boryung Pharmaceutical), a strong player in the domestic anticancer drug market, draws the industry’s attention by tying up with Bixink Therapeutics, which holds the domestic rights to Nerlynx Tablets (neratinib maleate), a new drug for HER2-positive breast cancer.Bixink Therapeuti